keyword
https://read.qxmd.com/read/38534996/novel-strategy-in-the-detection-of-adverse-cutaneous-drug-reactions-a-case-series-study
#1
JOURNAL ARTICLE
Erika-Gyöngyi Bán, Patrick Lechsner, Eszter-Anna Dho-Nagy, Maria-Antonia Balan, István Major-Szakács, Attila Brassai, Zsuzsánna Simon-Szabó, Corina Ureche
With multimorbidity on the rise, adverse cutaneous drug reactions are becoming a daily challenge in clinical practice. The objective evaluation of the skin lesion is crucial but hardly realized due to missing technology and guidelines. In this study, the novel Dermus SkinScanner-U, an optically guided high-frequency ultrasound imaging device, was evaluated regarding its comparability with the Dermatology Life Quality Index (DLQI) and the pharmacological analysis of the patients' drug therapy. A total of 40 adult patients were evaluated, all with chronic medication use and skin lesions that led to non-compliance toward the pharmacotherapy...
March 7, 2024: Diagnostics
https://read.qxmd.com/read/38534679/the-application-of-knowledge-based-clinical-decision-support-systems-to-detect-antibiotic-allergy
#2
JOURNAL ARTICLE
Nayoung Han, Ock Hee Oh, John Oh, Yoomi Kim, Younghee Lee, Won Chul Cha, Yun Mi Yu
Prevention of drug allergies is important for patient safety. The objective of this study was to evaluate the outcomes of antibiotic allergy-checking clinical decision support system (CDSS), K-CDSTM . A retrospective chart review study was performed in 29 hospitals and antibiotic allergy alerts data were collected from May to August 2022. A total of 15,535 allergy alert cases from 1586 patients were reviewed. The most frequently prescribed antibiotics were cephalosporins (48.5%), and there were more alerts of potential cross-reactivity between beta-lactam antibiotics than between antibiotics with the same ingredients or of the same class...
March 7, 2024: Antibiotics
https://read.qxmd.com/read/38528810/assessment-of-knowledge-and-attitudes-of-physicians-and-pharmacists-on-probiotics-a-cross-sectional-survey
#3
JOURNAL ARTICLE
Hülya Başar Güneş, Aygin Bayraktar Ekincioğlu, Tarkan Karakan, Kutay Demirkan
OBJECTIVES: Probiotics have been gaining increased attention from the public recently, which originates concerns about their rationale use among healthcare professionals. Although there is evidence on the efficacy and safety of probiotics in certain gastrointestinal disorders, it is important to identify healthcare professionals' opinions on probiotics. This study aimed to identify the opinions of pharmacists and physicians on the use of probiotics. MATERIALS AND METHODS: This cross-sectional study was conducted between November, 2017 and August, 2018 among pharmacists and physicians practicing in Ankara, Türkiye...
March 25, 2024: Turkish journal of pharmaceutical sciences
https://read.qxmd.com/read/38528712/effect-of-photodynamic-therapy-with-5-aminolevulinic-acid-and-edta-2na-against-mixed-infection-of-methicillin-resistant-staphylococcus-aureus-and-pseudomonas-aeruginosa
#4
JOURNAL ARTICLE
Rie Teranishi, Toshiyuki Ozawa, Bunpei Katayama, Yu Shimojo, Nobuhisa Ito, Kunio Awazu, Daisuke Tsuruta
BACKGROUND: The increasing abundance of drug-resistant bacteria is a global threat. Photodynamic therapy is an entirely new, non-invasive method for treating infections caused by antibiotic-resistant strains. We previously described the bactericidal effect of photodynamic therapy on infections caused by a single type of bacterium. We showed that gram-positive and gram-negative bacteria could be killed with 5-aminolevulic acid and 410 nm light, respectively. However, clinically, mixed infections are common and difficult to treat...
March 2024: Photodermatology, Photoimmunology & Photomedicine
https://read.qxmd.com/read/38524518/efficacy-of-borneol-gypsum-in-skin-regeneration-and-pain-control-in-toxic-epidermal-necrolysis-a-case-report
#5
Lu-Wei Yang, Li-Juan Zhang, Bin-Bin Zhou, Xin-Yu Lin, Yu-Ting Chen, Xiao-Yu Qin, Hui-Ying Tian, Li-Li Ma, Ying Sun, Lin-Di Jiang
BACKGROUND: Toxic epidermal necrolysis (TEN) is a life-threatening dermatological emergency mainly induced by drug hypersensitivity reactions. Standard management includes discontinuation of culprit drug and application of immunomodulatory therapy. However, mortality remains high due to complications like septic shock and multiorgan failures. Innovative approaches for skin care are crucial. This report introduces borneol-gypsum, a traditional Chinese drug but a novel dressing serving as an adjuvant of TEN therapy, might significantly improve skin conditions and patient outcomes in TEN...
March 6, 2024: World Journal of Clinical Cases
https://read.qxmd.com/read/38524393/a-case-of-vitiligo-combined-with-systemic-lupus-erythematosus-treated-with-tofacitinib
#6
Qingxia Lin, Jinrong Zhu, Xuelei Gao
Vitiligo is a skin depigmentation disease resulting from melanocyte destruction and often co-occurring with autoimmune disorders like hyperthyroidism, alopecia areata, pernicious anemia, and systemic lupus erythematosus (SLE). Although various traditional treatments exist for vitiligo, their effectiveness varies considerably. This report presents a unique case of a vitiligo patient with concomitant systemic lupus erythematosus. Remarkably, after a 30-day course of treatment with tofacitinib, complete repigmentation of the white macular rash was achieved, and there were no adverse drug reactions...
2024: Clinical, Cosmetic and Investigational Dermatology
https://read.qxmd.com/read/38523830/a-saudi-woman-with-ceftriaxone-induced-fixed-drug-eruption
#7
Rehab Y Al-Ansari, Leena Abdulrahman Almuhaish, Khaled Abdullah Hassan, Tawasoul Fadoul, Alexander Woodman
BACKGROUND: A fixed drug eruption (FDE) is an immunological cutaneous adverse reaction, classified as a cutaneous adverse drug reaction (CADR) and characterized by well-defined lichenoid lesions that occur at the same site each time. Ceftriaxone is a third-generation antibiotic of cephalosporin antibiotics of the beta-lactam antibiotic family, which has typical in vitro activity against many Gram-negative aerobic bacteria. This is the first clinical case from Saudi Arabia and the fifth in the world to document a woman's experience with recurrent FDE after repeated ceftriaxone use...
2024: Case Reports in Dermatological Medicine
https://read.qxmd.com/read/38523307/dermatological-side-effects-of-dipeptidyl-peptidase-4-inhibitors-in-diabetes-management-a-comprehensive-review
#8
REVIEW
Shirin Zaresharifi, Mahtab Niroomand, Sarina Borran, Sahar Dadkhahfar
Dipeptidyl peptidase-4 (DPP-4) inhibitors are a class of drugs that enhance the incretin-insulin pathway and offer effective glycemic control in type 2 diabetes mellitus. However, these drugs may be associated with various dermatological side effects, ranging from mild to severe. This review article summarizes the current literature on the dermatological side effects of DPP-4 inhibitors, including bullous pemphigoid, severe cutaneous adverse drug reactions, fixed drug eruptions, and other mucocutaneous reactions...
March 25, 2024: Clinical Diabetes and Endocrinology
https://read.qxmd.com/read/38522573/strategy-for-the-optimization-of-read-through-therapy-for-junctional-epidermolysis-bullosa-with-col17a1-nonsense-mutation
#9
JOURNAL ARTICLE
Saliha Beyza Sayar, Cristina Has
The read-through therapy suppresses premature termination codons and induces read-through activity consequently restoring missing proteins. Aminoglycosides are widely studied as read-through drugs in different human genetic disorders including hereditary skin diseases. Our previous work revealed that aminoglycosides have effect on COL17A1 nonsense mutations and represent a therapeutic option to alleviate disease severity. However, the amount of restored type XVII collagen (C17) in C17 deficient junctional epidermolysis bullosa (JEB-C17) keratinocytes was less than 1% relative to normal keratinocytes and was achieved only after high dose gentamicin treatment, which induced deep transcriptional changes...
March 22, 2024: Journal of Investigative Dermatology
https://read.qxmd.com/read/38521706/targeted-therapy-for-immune-mediated-skin-diseases-what-should-a-dermatologist-know
#10
REVIEW
Edinson López, Raúl Cabrera, Cristóbal Lecaros
BACKGROUND: Molecularly targeted therapies, such as monoclonal antibodies (mAbs) and Janus Kinase inhibitors (JAKis), have emerged as essential tools in the treatment of dermatological diseases. These therapies modulate the immune system through specific signaling pathways, providing effective alternatives to traditional systemic immunosuppressive agents. This review aims to provide an updated summary of targeted immune therapies for inflammatory skin diseases, considering their pathophysiology, efficacy, dosage, and safety profiles...
March 22, 2024: Anais Brasileiros de Dermatologia
https://read.qxmd.com/read/38518171/clinical-evaluation-of-a-topical-unani-polyherbal-formulation-in-the-management-of-photodamaged-facial-skin-an-open-label-standard-controlled-trial
#11
JOURNAL ARTICLE
Chand Bibi, Zar Nigar
INTRODUCTION: Ageing is a natural process of life. With increasing age, the skin suffers progressive morphological and physiological decrement. Hyperpigmentation, Wrinkles, and roughness of skin are some of the symptoms of aged skin. Exposure to sunlight, pollution, stress, nicotine, etc aggravates Skin aging. This study aimed to determine the efficacy and safety of polyherbal formulation and compare its efficacy with the standard drug tretinoin in subjects of moderate to advanced Photoaged facial skin...
March 22, 2024: Alternative Therapies in Health and Medicine
https://read.qxmd.com/read/38517652/efficacy-and-safety-of-tofacitinib-for-chronic-plaque-psoriasis-and-psoriatic-arthritis-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials
#12
JOURNAL ARTICLE
Qianqian Dai, Yanfeng Zhang, Qian Liu, Chijin Zhang
OBJECTIVES: To summarize and analyze the results of published randomized controlled trials of tofacitinib for the treatment of chronic plaque psoriasis and psoriatic arthritis(PsA) and discuss its efficacy and safety. PATIENTS AND METHODS: An exhaustive systematic search encompassing PubMed, Cochrane, Embase, and Web of Science databases was conducted up to July 2023. Studies eligible for inclusion were analyzed, organized using Review Manager version 5.4.1 (Cochrane Collaboration, Oxford, UK) and STATA 15...
March 22, 2024: Clinical Rheumatology
https://read.qxmd.com/read/38515844/case-report-minocycline-induced-drug-reaction-with-eosinophilia-and-systemic-symptoms-syndrome-a-case-report-and-literature-review
#13
Zhe Zhao, Ming Lu, Yingqiu Ying
Minocycline is a tetracycline commonly used for several dermatological diseases. Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a rare but severe adverse event which can be caused by minocycline. An 18-year-old male patient developed fever, acute rash, pharyngeal pain, lymphadenopathy, hematologic abnormalities, increased creatinine level, elevated liver enzyme levels, and splenomegaly 4 weeks after the oral treatment of minocycline, 100 mg daily, for acne. Once diagnosed with DRESS syndrome, intravenous methylprednisolone was applied and his clinical manifestations and laboratory results remarkably improved...
2024: Frontiers in Pharmacology
https://read.qxmd.com/read/38514926/fucoidan-suppresses-proliferation-and-epithelial-mesenchymal-transition-process-via-wnt-%C3%AE-catenin-signalling-in-hemangioma
#14
JOURNAL ARTICLE
Zhengyumeng Zhu, Jialiang Luo, Lei Li, Di Wang, Qishan Xu, Jianan Teng, Jia Zhou, Ledong Sun, Nansheng Yu, Daming Zuo
Hemangioma is a common benign tumour that usually occurs on the skin of the head and neck, particularly among infants. The current clinical treatment against hemangioma is surgery excision, however, application of drug is a safer and more economical therapy for children suffering from hemangioma. As a natural sulfated polysaccharide rich in brown algae, fucoidan is widely recognized for anti-tumour bioactivity and dosage safety in humans. This study aims to demonstrate the anti-tumour effect and underlying mechanism of fucoidan against hemangioma in vivo and in vitro...
March 2024: Experimental Dermatology
https://read.qxmd.com/read/38513820/paradoxical-psoriasis-from-its-many-faces-to-possible-shared-therapeutic-targets
#15
JOURNAL ARTICLE
Carlo Alberto Maronese, Antonio Costanzo, Michel Gilliet, Angelo Valerio Marzano
No abstract text is available yet for this article.
March 19, 2024: Journal of Investigative Dermatology
https://read.qxmd.com/read/38513258/comparison-between-super-responders-and-non-super-responders-in-psoriasis-under-adalimumab-treatment-a-real-life-cohort-study-on-the-effectiveness-and-drug-survival-over-one-year
#16
JOURNAL ARTICLE
Yizhang Liu, Kun Hu, Lu Jian, Yongfang Duan, Mi Zhang, Yehong Kuang
BACKGROUND: Data on the characteristics and treatment outcomes of super-responders and non-super-responders in psoriasis under adalimumab treatment are limited. METHODS: A retrospective analysis from psoriatic patients treated with adalimumab was compared to characterize super-responders vs non-super-responders' groups, identify factors associated with super response, and assess treatment outcomes after switching. RESULTS: 15 out of 70 (21...
December 2024: Journal of Dermatological Treatment
https://read.qxmd.com/read/38511567/natural-products-of-plant-origin-an-emerging-therapeutic-for-dermatomycosis
#17
REVIEW
Mangal C Biswas, Khushi Mukherjee, Sandipta Ghosh, Moytri Roy-Chowdhury, Krishnendu Acharya
Dermatomycosis or superficial mycosis is considered one of the chronic fungal infections and a global challenge for the public health system. The severity of dermatomycosis is proportionately increasing with the emerging population of immunocompromised individuals, and it is becoming more prevalent, even life-threatening, in several tropical countries. In this context, improper long-term treatment with synthetic antifungal drugs and their related side effects imposes additional challenges in treating dermatomycosis...
March 21, 2024: International Journal of Dermatology
https://read.qxmd.com/read/38509804/drug-survival-of-biologics-in-psoriasis-an-australian-multicentre-retrospective-study
#18
JOURNAL ARTICLE
Samantha Ting, Patricia Lowe, Annika Smith, Pablo Fernández-Peñas
BACKGROUND: Drug survival, which refers to the time from treatment initiation to discontinuation, provides a surrogate measure of the effectiveness of a biologic in a real-world setting (J Invest Dermatol, 2015, 135, 1). The aim of this study was to determine the drug survival of biologics that are currently available in Australia. We also analysed the treatment efficacy of these biologics and reasons for discontinuation. METHODS: Retrospective data from outpatient Dermatology biologic clinics in Westmead Hospital and Royal Prince Alfred Hospital (Sydney, Australia) from April 2006 to December 2020 were collected...
March 21, 2024: Australasian Journal of Dermatology
https://read.qxmd.com/read/38509717/nectin4-targeted-antibody-drug-conjugate-is-a-potential-therapeutic-option-for-extramammary-paget-disease
#19
JOURNAL ARTICLE
Yuka Tanaka, Takamichi Ito, Maho Murata, Keiko Tanegashima, Yumiko Kaku-Ito, Takeshi Nakahara
Extramammary Paget disease (EMPD) is a rare skin cancer mainly found in areas rich in apocrine sweat glands. Since the effective treatments for advanced and/or metastasized EMPD are limited, there is an urgent need to develop novel therapeutic approaches. Nectin cell adhesion molecule 4 (NECTIN4) is highly expressed in cancers and considered to be a promising therapeutic target. NECTIN4 is also expressed in EMPD, but its role and the efficacy of NECTIN4-targeted therapy in EMPD remain unclear. This study investigated the potential of NECTIN4 as a novel therapeutic target for EMPD...
March 2024: Experimental Dermatology
https://read.qxmd.com/read/38509380/management-of-patients-affected-by-moderate-to-severe-atopic-dermatitis-with-jak-inhibitors-in-real-world-clinical-practice-an-italian-delphi-consensus
#20
JOURNAL ARTICLE
Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, Anna G Burroni, Andrea Chiricozzi, Paolo Dapavo, Silvia M Ferrucci, Massimo Gola, Maddalena Napolitano, Michela Ortoncelli, Maria T Rossi, Claudio Sciarrone, Antonio Costanzo, Alessandra Narcisi
INTRODUCTION: Several systemic therapies have been approved for the treatment of severe AD. In particular, Janus kinase inhibitors (JAKi), including abrocitinib, baricitinib, and upadacitinib, recently received approval for the treatment of patients with severe AD after being evaluated in several clinical trials. However, a few concerns have been raised regarding their long-term safety and the management of these drugs in real-world clinical practice. In this article we described the results of a Delphi consensus aimed at describing the knowledge on JAKi and focusing, in particular, on providing clinical recommendations for dermatologists in daily practice regarding the use of these drugs...
March 21, 2024: Dermatology and Therapy
keyword
keyword
86552
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.